A noncomparative randomized phase II study of two dose levels of itraconazole in men with metastatic castration-resistant prostate cancer (mCRPC): A DOD/PCCTC trial.

被引：0
|
作者：
Antonarakis, E. S.
Heath, E. I.
Smith, D. C.
Rathkopf, D. E.
Blackford, A. L.
Danila, D. C.
King, S.
Frost, A.
Carducci, M. A.
机构：
[1] Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA
[2] Karmanos Canc Inst, Detroit, MI USA
[3] Univ Michigan, Ann Arbor, MI 48109 USA
[4] Mem Sloan Kettering Canc Ctr, Sidney Kimmel Ctr Prostate & Urol Canc, New York, NY 10021 USA
[5] Johns Hopkins Univ, Sch Med, Baltimore, MD USA
[6] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 15期
关键词：
D O I：
10.1200/jco.2011.29.15_suppl.4532
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4532
引用
收藏
页数：1
相关论文
共 50 条
  • [21] A phase II study of sEphB4-HSA in metastatic castration-resistant prostate cancer (mCRPC)
    Burns, Michael C.
    Sagar, Vinay
    Jovanovic, Borko
    Morgans, Alicia K.
    VanderWeele, David James
    Quinn, David I.
    Stadler, Walter Michael
    Abdulkadir, Sarki
    Hussain, Maha H. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [22] Phase II cohort study in patients with metastatic castration-resistant prostate cancer (mCRPC) with new cohorts
    Rexer, Heidrun
    Retz, Margitta
    Hammerer, Peter
    AKTUELLE UROLOGIE, 2022, 53 (06) : 504 - 505
  • [23] Phase II trial of bevacizumab and lenalidomide with docetaxel and prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC)
    Adesunloye, Bamidele
    Huang, Xuan
    Ning, Yangmin M.
    Madan, Ravi A.
    Gulley, James L.
    Beatson, Melony
    Kluetz, Paul Gustav
    Adelberg, David
    Arlen, Philip M.
    Parnes, Howard L.
    Mulquin, Marcia
    Steinberg, Seth M.
    Wright, John Joseph
    Trepel, Jane B.
    Dawson, Nancy Ann
    Chen, Clara
    Apolo, Andrea Borghese
    Figg, William Douglas
    Dahut, William L.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (05)
  • [24] Randomized phase II study of nintedanib in metastatic castration-resistant prostate cancer postdocetaxel
    Droz, Jean-Pierre
    Medioni, Jaques
    Chevreau, Christine
    De Mont-Serrat, Helene
    Merger, Michael
    Stopfer, Peter
    Kaiser, Rolf
    Oudard, Stephane
    ANTI-CANCER DRUGS, 2014, 25 (09) : 1081 - 1088
  • [25] ARN-509 in men with metastatic castration-resistant prostate cancer (mCRPC)
    Rathkopf, Dana E.
    Antonarakis, Emmanuel S.
    Shore, Neal D.
    Tutrone, Ronald
    Alumkal, Joshi J.
    Ryan, Charles J.
    Saleh, Mansoor N.
    Hauke, Ralph J.
    Maneval, Edna Chow
    Scher, Howard I.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (06)
  • [26] Pembrolizumab in men with heavily treated metastatic castration-resistant prostate cancer (mCRPC).
    Tucker, Matthew D.
    Zhu, Jason
    Berry, William R.
    Ramalingam, Sundhar
    Zhang, Tian
    Harrison, Michael Roger
    Wu, Yuan
    Healy, Patrick
    George, Daniel J.
    Armstrong, Andrew J.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [27] Phase Ib trial of cabazitaxel and tasquinimod in men with heavily pretreated metastatic castration resistant prostate cancer (mCRPC): The CATCH trial.
    Armstrong, Andrew J.
    Healy, Patrick
    Szmulewitz, Russell Zelig
    Winters, Carolyn
    Harrison, Michael Roger
    Martinez, Elia
    Mundy, Kelly
    Halabi, Susan
    George, Daniel J.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (02)
  • [28] Randomized Phase II Cabazitaxel Dose Individualization and Neutropenia Prevention Trial in Patients with Metastatic Castration-Resistant Prostate Cancer
    Omlin, Aurelius
    Cathomas, Richard
    von Amsberg, Gunhild
    Reuter, Christoph
    Feyerabend, Susan
    Loidl, Wolfgang
    Boegemann, Martin
    Lorch, Anja
    Heidenreich, Axel
    Tsaur, Igor
    Larcher-Senn, Julian
    Buck, Stefan A. J.
    Mathijssen, Ron H. J.
    Jaehde, Ulrich
    Gillessen, Silke
    Joerger, Markus
    CLINICAL CANCER RESEARCH, 2023, 29 (08) : 1887 - 1893
  • [29] Dexamethasone in pretreated men with metastatic castration-resistant prostate cancer (mCRPC): A prospective study.
    Baciarello, Giulia
    Hamilou, Zineb
    Chebib, Ralph
    Albiges, Laurence
    Fuerea, Alina
    Loriot, Yohann
    Massard, Christophe
    Colomba, Emeline
    Di Palma, Mario
    Escudier, Bernard
    Fizazi, Karim
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
  • [30] A prospective randomized phase II trial evaluating maintenance GM-CSF in an intermittent chemotherapy (chemo) regimen for metastatic castration-resistant prostate cancer (mCRPC): A DoD prostate cancer clinical trials consortium trial
    Small, Eric Jay
    Weinberg, Vivian K.
    Ryan, Charles J.
    Higano, Celestia S.
    Lin, Amy Mimi
    Maruca, Yvonne
    Alumkal, Joshi J.
    Yu, Evan Y.
    Rosenberg, Jonathan E.
    Beer, Tomasz M.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (05)
12345